EGFR and non-small cell lung carcinoma: In this cohort, younger age, current smoking, PS ≥ 2, weight loss ≥10%, shorter time since diagnosis, pathological classification as non-otherwise-specified NSCLC, and the presence of abdominal metastasis were associated with early progression of NSCLC with EGFR-TKI therapy.